Dual Strategy to Design New Agents Targeting Schistosoma mansoni : Advancing Phenotypic and Sm CB1 Inhibitors for Improved Efficacy
ACS Infectious Diseases · 2024
DOI: 10.1021/acsinfecdis.4c00020 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, 2024. Verfasst von Natalie Fuchs und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University Mainz, Staudingerweg 5, 55128 Mainz, Germany. Hauptthemen laut MEDLINE: Schistosoma mansoni, Cathepsin B. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University Mainz, Staudingerweg 5, 55128 Mainz, Germany.
- Swiss Tropical and Public Health Institute, Kreuzstrasse 2, 4123 Allschwil, Switzerland.
ORCID-Profile: Natalie Fuchs, Robert A Zimmermann, Marvin Schwickert, Mergim Meta
Zitieren
APA
Fuchs, N., Zimmermann, R. A., Schwickert, M., Gunkel, A., Zimmer, C., Meta, M., Schwickert, K., Keiser, J., Haeberli, C., Kiefer, W., & Schirmeister, T. (2024). Dual Strategy to Design New Agents Targeting Schistosoma mansoni : Advancing Phenotypic and Sm CB1 Inhibitors for Improved Efficacy. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.4c00020
Vancouver
Fuchs N, Zimmermann RA, Schwickert M, Gunkel A, Zimmer C, Meta M, et al. Dual Strategy to Design New Agents Targeting Schistosoma mansoni : Advancing Phenotypic and Sm CB1 Inhibitors for Improved Efficacy. ACS Infectious Diseases. 2024. doi:10.1021/acsinfecdis.4c00020
BibTeX
@article{Fuchs2024,
author = {Fuchs, Natalie and Zimmermann, Robert A and Schwickert, Marvin and Gunkel, Annika and Zimmer, Collin and Meta, Mergim and Schwickert, Kevin and Keiser, Jennifer and Haeberli, Cécile and Kiefer, Werner and Schirmeister, Tanja},
title = {Dual Strategy to Design New Agents Targeting Schistosoma mansoni : Advancing Phenotypic and Sm CB1 Inhibitors for Improved Efficacy},
journal = {ACS Infectious Diseases},
year = {2024},
doi = {10.1021/acsinfecdis.4c00020}
}
EUVIMED